Current stock page

Financial Data

LGND Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

LGNDLigand Pharmaceuticals Incorporated

Healthcare / Biotechnology

Leader

Sector Leader

BullishEdge 10/10
$308.79−$7.48 (−2.37%)

Latest quote

  • Momentum
    86
  • Value
    61
  • Quality
    76
  • Risk resilience
    70
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$78.75M$63.69M$51.72M$59.67M$115.46M$47.63M$45.33M$42.81M
Gross Profit$76.1M$60.48M$49.65M$85.65M$90.64M$44.72M$40.48M$39.98M
Operating Income-$15.76M$8.59M$17.37M$20.04M$54.93M$8.44M-$36.22M-$9.64M
Net Income-$28.49M$48.51M-$13.35M$44.78M$117.27M$4.85M-$42.45M-$31.09M
EPS-$1.43$2.42-$0.67$2.27$5.99$0.25-$2.21-$1.64
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$27.59M$24.02M$48.69M$45.84M$13.09M$15.8M-$25.52M$28.47M
Capital Expenditure-$142K-$26K-$228K-$9K-$15K-$214K-$214K-$712K
Free Cash Flow-$27.73M$23.99M$48.46M$45.84M$13.08M$15.58M-$25.73M$27.76M
Net Cash Provided By Operating Activities-$27.59M$24.02M$48.69M$45.84M$13.09M$15.8M-$25.52M$28.47M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$2.24B$2.19B$1.53B$1.56B$1.48B$948.6M$905.44M$941.77M
Total Debt$1.15B$1.13B$451.98M$451.49M$451M$5.74M$4.45M$7.11M
Cash And Cash Equivalents$55.96M$1.01B$115.08M$174.93M$139.38M$67.67M$47.99M$72.31M
Total Liabilities$1.28B$1.22B$534.78M$543.43M$526.6M$120.08M$109.9M$111.34M
Total Stockholders Equity$961.76M$967.52M$997.32M$1.02B$950.17M$828.53M$795.53M$830.44M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio115.9832.4628.6733.6884.07———
P/B ratio6.216.624.414.124.33.612.522.79
P/S ratio24.28———————
Debt To Equity1.21.170.450.440.470.010.010.01
Free Cash Flow Yield1.52%2.05%2.79%1.16%0.75%1.33%1.77%3.44%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio115.9832.4628.6733.6884.07———
P/B ratio6.216.624.414.124.33.612.522.79
P/S ratio24.28———————
Return On Equity5.35%20.38%15.40%12.23%5.11%-9.16%-16.67%-0.49%
Debt To Equity1.21.170.450.440.470.010.010.01

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe119.22x
Pb6.41x
Revenue Growth Yoy-31.80%
EPS Growth Yoy-123.87%
Gross Margin107.11%
Operating Margin11.91%
ROE5.22%
ROIC1.35%
Debt To Equity1.2
FCF Yield1.47%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$308.79
Volume135,792
RSI (14)50.19
MACD3.02
MACD signal3.48
MACD histogram-0.46
ADX (14)15.12
SMA (50)$301.71
SMA (200)$258.37
ATR (14)$11.33
Historical volatility (annualized)38.54%
Volume (20-day average)214,441

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score70/100
Beta0.89
Annual volatility36.55%
Max Drawdown-14.70%
Sharpe Ratio1.25
VaR (95%, 1-day)-3.16%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

LGND Financial Data FAQ

What is Ligand Pharmaceuticals Incorporated's revenue?

Ligand Pharmaceuticals Incorporated's revenue is one of the core financial data points for LGND. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Ligand Pharmaceuticals Incorporated's revenue growing?

Revenue growth shows whether Ligand Pharmaceuticals Incorporated is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is LGND's EPS?

LGND's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Ligand Pharmaceuticals Incorporated's net income?

Ligand Pharmaceuticals Incorporated's net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Ligand Pharmaceuticals Incorporated generate?

Free cash flow shows how much cash Ligand Pharmaceuticals Incorporated generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Ligand Pharmaceuticals Incorporated have?

Cash and debt help frame LGND's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.